[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back

Go back to trials list

A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ONO-7018 in Patients With Relapsed or Refractory NHL or CLL


Description

This is a Phase 1, open-label, multicenter study. This will be the first-in-human clinical study for ONO-7018 and will be conducted in two phases: a Dose Escalation Phase (Part 1) and a Dose Expansion Phase (Part 2).ONO-7018 is a selective inhibitor of mucosa associated lymphoid tissue protein 1 (MALT1) and is expected to exhibit antitumor activity in NHL and CLL. The purpose of this study is to determine the MTD and to evaluate the safety, tolerability, PK, pharmacodynamics (biomarkers), and efficacy of ONO-7018 in patients with relapsed or refractory NHL or CLL.

Trial Eligibility

Inclusion Criteria: 1. Patient aged ≥ 18 years 2. Written informed consent by the patient or the patient's legally authorized representative 3. Patient with histologically/cytologically confirmed diagnosis of NHL or CLL 4. Patient with relapsed or refractory disease who has no available therapeutic options known to provide clinical benefit 5. Patient who has measurable disease 6. All acute toxic effects of any prior antitumor therapy, including investigational therapy, resolved to Grade ≤ 1 before the start of study therapy 7. Eastern Cooperative Oncology Group Performance Status 0 to 2 8. Adequate bone marrow, renal and hepatic functions Exclusion Criteria: 1. History of lymphoid malignancy other than those allowed per inclusion criteria 2. Patient with central nervous system involvement 3. Patient with systemic and active infection 4. Any serious or uncontrolled medical disorder that may increase the risk associated with study participation or study treatment, or interfere with the interpretation of study results 5. Prior treatment with a MALT1 inhibitor 6. Patient receiving any other investigational drug within 4 weeks prior to study entry 7. Patient is unable to swallow tablets 8. Patient is found to be otherwise ineligible for the study by the investigator or sub investigator

Study Info

Organization

Ono Pharmaceutical Co. Ltd


Primary Outcome

Estimate of Maximum Tolerated Dose (MTD)


Outcome Timeframe Up to 3 weeks

NCTID NCT05515406

Phases PHASE1

Primary Purpose TREATMENT

Start Date 2023-02-13

Completion Date 2027-12

Enrollment Target 108

Interventions

DRUG ONO-7018

DRUG ONO-7018

Locations Recruiting

Jonsson Comprehensive Cancer Center

United States, California, Santa Monica


Emory University Hospital

United States, Georgia, Atlanta


Dana-Farber Cancer Institute

United States, Massachusetts, Boston


AMR Kansas City

United States, Missouri, Kansas City


Summit Medical Group

United States, New Jersey, Florham Park


Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.

newsletter icon

Get the latest thought leadership on your Blood Cancer delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.